Abstract:Objective To develop an LC-MS/MS method for simultaneous determine the concentration of atorvastatin (AT) and its two active metabolites,ortho-hydmxyatorvastatin (o-AT) andpara-hydroxyatorvastatin (p-AT) in human plasma.Methods Deuterium-labeled compounds,o-AT-d5 and p-AT-d5were used as the internal standards.The analytes were extracted from human plasma through liquid liquid extraction method by using tert-butyl ether,after adding 5％ formic acid.The chromatographic separation was achieved on a CAPCELL PAK C18(2.0 mm× 100 mm,TYPE∶MG Ⅱ,5 μm) column with the mobile phase,consisted of a mixture of acetonitrile-5 mmol · L-1 ammonium acetate buffer-formic acid (46∶ 54∶ 0.143,v/v/v),in isocratic mode at a flow rate of 0.40 mL · min-1.Data acquisition was carried out in multiple reaction monitoring (MRM) mode.Analytes were detected on a tandem mass spectrometer,equipped with an electrospray ionization source that was operated in the positive mode,using the transitions of m/z 559.3→m/z 440.2 for atorvastatin,and m/z 575.3→m/z 440.2 for both ortho-and para-hydroxyatorvastatin.The selectivity,standard curve,precision and accuracy,extraction recoveries,matrix effect,carry over and stability were investigated.Results The linear range of atorvastatin was 0.05-100 ng · mL-1.The linear regression equation was y =4.35 × 10-2x + 3.43 × 10-4 (r =0.999 3) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The linear range of ortho-atorvastatin was 0.05-50 ng· mL-1.The linear regression equation was y =1.03 × 10-1x + 6.93 × 10-4 (r =0.998 7) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The linear range of para-atorvastatin was 0.05-5.0 ng · mL-1.The linear regression equation was y =5.35 × 10-1 x-2.26 × 10-3 (r =0.998 4) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The intra-day and inter-day relative standard deviations (RSD) of LLOQ,low,medium1,medium2 and high concentrations of atorvastatin were both less than 15％.The extraction recoveries were 61.64％-90.29％.The matrix effects were 88.74％-105.62％.Conclusion The established method is rapid,sensitive,accurate,specific and reliable,and suitablefor simultaneous determination of atorvastatin and its active metabolites (ortho-atorvastatin and para-atorvastatin) in human plasma,which meets the needs of clinical therapeutic drug monitoring and pharmacokinetics research.

Development and validation of a liquid chromatography–tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its application in a bioequivalence study

High-Performance Liquid Chromatography-Mass Spectrometric Analysis of Ramipril and Its Active Metabolite Ramiprilat in Human Serum: Application to A Pharmacokinetic Study in the Chinese Volunteers

Simultaneous determination of atorvastatin and its active metabolites in human plasma by LC-MS/MS

Determination of Amlodipine Concentration in Human Plasma by LC-MS/MS Method and Bioequivalence Study of Its Tablets

Simultaneous Determination of Amlodipine and Bisoprolol in Rat Plasma by a Liquid Chromatography/tandem Mass Spectrometry Method and Its Application in Pharmacokinetic Study.

HPLC–MS–MS for the Simultaneous Determination of Atorvastatin and Amlodipine in Plasma of Hypertensive Patients

Sensitive Determination and Pharmacokinetic Study of Amlodipine in Human Serum by LC-ESI/MS/MS

Stability‐indicating RP‐HPLC method development and validation for the quantification of amlodipine besylate and valsartan tablets in solid oral dosage form

Development and Validation of a Method for Quantification of Lisinopril, Indapamide, Metoprolol, Valsartan, and Amoldipine in Human Blood Serum by HPLC-MS/MS

Development and validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of four tertiary alkaloids in rat plasma and its application to a pharmacokinetic study.

Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study

An improved LC-MS/MS method for the quantification of alverine and para hydroxy alverine in human plasma for a bioequivalence study☆

Simultaneous determination of amoxicillin and ambroxol in human plasma by LC-MS/MS: validation and application to pharmacokinetic study

Simultaneous Determination of Paracetamol and Amantadine in Human Plasma and Bioequivalence of Its Preparations in Healthy Volunteers by LC-MS

Development, validation and long-term evaluation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of amiodarone, desethylamiodarone and mexiletine in human plasma and serum

Simultaneous Determination of Hydrochlorothiazide and Valsartan in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry

Determination of losartan and its metabolite in human plasma by LC-MS/MS and bioequi valence study of losartan potassium tablets

Development and Validation of Ultra-Performance Liquid Chromatography (UPLC) Method for Simultaneous Quantification of Hydrochlorothiazide, Amlodipine Besylate, and Valsartan in Marketed Fixed-Dose Combination Tablet

Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma.

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma.

Rapid and sensitive liquid chromatography tandem mass spectrometry method for the quantification of ambroxol in human plasma.